Development
Recursion Pharmaceuticals, Inc.
RXRX
$5.49
$0.9220.13%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 11.88% | 65.02% | 176.57% | 260.21% | 291.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.88% | 65.02% | 176.57% | 260.21% | 291.46% |
| Cost of Revenue | -11.78% | -47.54% | -54.75% | -55.64% | -64.31% |
| Gross Profit | 123.56% | 66.69% | 81.49% | 85.18% | 93.26% |
| SG&A Expenses | 31.32% | 25.78% | 19.39% | 21.79% | 46.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.85% | 29.71% | 29.87% | 39.18% | 49.45% |
| Operating Income | -40.86% | -25.65% | -18.51% | -25.44% | -35.98% |
| Income Before Tax | -38.69% | -18.49% | -11.15% | -17.51% | -28.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.99% | -18.49% | -11.15% | -17.51% | -28.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.99% | -18.49% | -11.15% | -17.51% | -28.42% |
| EBIT | -40.86% | -25.65% | -18.51% | -25.44% | -35.98% |
| EBITDA | -37.55% | -22.92% | -17.01% | -25.20% | -35.79% |
| EPS Basic | -15.05% | -1.72% | -0.47% | -5.60% | 40.88% |
| Normalized Basic EPS | -15.06% | -2.37% | -1.51% | -6.70% | 40.10% |
| EPS Diluted | -15.05% | -1.72% | -0.47% | -5.60% | 40.88% |
| Normalized Diluted EPS | -15.06% | -2.37% | -1.51% | -6.70% | 40.10% |
| Average Basic Shares Outstanding | 18.31% | 15.65% | 10.48% | 11.74% | 40.60% |
| Average Diluted Shares Outstanding | 18.31% | 15.65% | 10.48% | 11.74% | 40.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |